Miralles Gines Diego sold 1,043 shares of Artiva Biotherapeutics, Inc. at $3.91 for −$4.08k on Nov 17, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
President & Head of R&D
President & Head of R&D
Filed Nov 18, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$4,080.11Shares × reported price
Shares traded
1,043Common Stock
Price per share
$3.91Reported price. Read footnotes for ranges.
% of reported position traded
0.85%This security and ownership context
Holdings after
121,457Direct
Trade date
Nov 17, 2026Sell
Filed
Nov 18, 2026, 4:06 PM ET1-day reporting delay
Accession
0001193125-26-467092Code S · Transaction 405665
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 122,500 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

ARTV price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
ARTV · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 25, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago +55%1w ago +7.4%1d ago +5%
Returns since7d30d90d180d1y

Footnotes in full

F1: The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.